False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay
Authors:
- 1 August 2013
- journal article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 394 (1-2) , 22-31
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Novel CD20 monoclonal antibodies for lymphoma therapyJournal of Hematology & Oncology, 2012
- The European Medicines Agency Review of Ofatumumab (Arzerra®) for the Treatment of Chronic Lymphocytic Leukemia in Patients Refractory to Fludarabine and Alemtuzumab: Summary of the Scientific Assessment of the European Medicines Agency Committee for Medicinal Products for Human UseThe Oncologist, 2010
- The clinical application of monoclonal antibodies in chronic lymphocytic leukemiaBlood, 2010
- Microvesicles: mediators of extracellular communication during cancer progressionJournal of Cell Science, 2010
- Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progressionBlood, 2010
- OfatumumabmAbs, 2009
- Membrane vesicles as conveyors of immune responsesNature Reviews Immunology, 2009
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysisAnnals of Hematology, 2007
- The epitope recognized by rituximabBlood, 2006